Adam D. Cohen

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations

Medicine, Hematology, Oncology +17

CRISPR-engineered T cells in patients with refractory cancer

Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis et al. · Science · 2020 · 1.4K citations · Full text

Life Sciences, Biotechnology, Immunology +17

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand et al. · Journal of Clinical Oncology · 2016 · 1K citations · Full text

Medicine, Hematology, Oncology +17

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

Medicine, Pharmacology, Pharmacotherapy +11

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer et al. · Journal of Clinical Investigation · 2019 · 790 citations · Full text

Life Sciences, Hematology, Immunology +17